Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger JW Jr, Cestari D, Mallery R, Abbasi B, Bouffard M, Chwalisz BK, Estrela T, Rizzo JF
This unique formula activates GLP-1 and CB2 receptors to help reduce appetite, promote faster and longer-lasting fullness, support healthy glucose metabolism and craving control, and enhance mood and energy levels
Niazi explains that tirzepatide is a newer dual-agonist that targets both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, which he says offers superior metabolic regulation and appetite suppression. Mounjaro is currently FDA-approved for type 2 diabetes, and Zepbound is also FDA-approved for weight loss
Most clients feel it in their skin, their energy, and their overall brightness usually within a day or two
longer-term durability beyond that timeframe remains under study
Wise BL, Seidel MF, Lane NE